DaltonTx, a UK-based technology company, has emerged from stealth mode with the completion of a £4 million seed financing round aimed at building adaptive AI-enabled discovery platforms that could fundamentally reshape the economics, timelines, and outcomes of pharmaceutical R&D. The funding round was led by redalpine, IQ Capital Partners, and Seedcamp, with additional support from Oxford University Innovation.
Addressing Critical Industry Challenges
The pharmaceutical industry faces a unique opportunity to leverage AI for more effective and efficient drug discovery, but building adaptive AI platforms requires years of investment in software engineering coupled with deep understanding of the underlying science and technology. DaltonTx addresses this challenge with a disease- and technology-agnostic adaptive platform that plugs directly into pharma, biotech, and CRO workflows, giving teams instant access to AI-enabled discovery instead of spending years developing these capabilities in-house.
"AI offers an opportunity to transform drug discovery, but it is still incredibly challenging for organisations to build their own capabilities," said Dr Garry Pairaudeau, Co-Founder of DaltonTx. "DaltonTx exists to change that. We are solving high-impact challenges with adaptive AI-enabled systems that integrate into scientific workflows, evolve with every experiment, and give organisations lasting AI capability."
Beyond Predictive Modeling
Built by scientists for scientists, DaltonTx goes beyond predictive modelling to power the full discovery process—from raw data and model training to molecular design, synthesis, and decision-making. The platform functions as an adaptive reasoning engine that learns from every scientist, model, and experiment to continuously improve outcomes.
The platform is purpose-built for both small molecules and biologics, making it uniquely suited to support the most complex R&D pipelines. Furthermore, DaltonTx enables collaborative intelligence, allowing scientists to interact with the system and combine their expertise with an engine that iterates and learns, effectively merging human insight with machine learning capabilities.
"At DaltonTx, we're generating biological and chemical insight that was previously out of reach," said Professor Charlotte Deane MBE, Co-Founder of DaltonTx and Professor of Structural Bioinformatics at the University of Oxford. "By combining cutting-edge machine learning with deep drug discovery expertise, we are creating technology that learns with every experiment and helps scientists turn ideas into impact."
Experienced Leadership Team
DaltonTx was co-founded by Dr Garry Pairaudeau, Adrian Rossall, Dr Anthony Bradley, and Professor Charlotte Deane MBE. The founding team combines decades of real-world experience in drug discovery, machine learning, and software engineering, having built pioneering AI discovery platforms at AstraZeneca and Exscientia while bringing world-leading academic research from the University of Oxford.
Investor Confidence
The seed funding reflects strong investor confidence in DaltonTx's potential to transform the drug discovery landscape. "DaltonTx is poised to become the intelligence backbone of drug discovery, providing scientific reasoning capabilities and deep integration into real drug discovery workflows. Led by a highly impressive team of industry experts, we believe the DaltonTx platform will soon be indispensable for every R&D organization across pharma, biotech, and CROs," said Marc Moesser, Investment Manager at redalpine.
Mason Sinclair, Principal at IQ Capital, added: "We are excited to back DaltonTx, a company poised to set a new standard in R&D execution. By combining world-class science with cutting-edge AI, the DaltonTx team is building the adaptive infrastructure that modern drug discovery needs."
Tom Wilson, Partner at Seedcamp, emphasized the strength of the founding team: "What impressed us most about DaltonTx is the strength and depth of the founding team. Their unique combination of drug discovery, machine learning, and software engineering expertise positions them to lead the next generation of AI in pharma."
Strategic Positioning
Based in London's King's Cross tech and life sciences hub, DaltonTx is strategically positioned at the intersection of engineering, AI, and drug discovery. The company aims to redefine how technology powers drug discovery by creating what it describes as "the intelligence engine behind tomorrow's medicines."
The adaptive AI platform is designed to provide pharma, biotech, and CROs with the intelligence backbone that modern R&D requires, transforming not just the speed but also the fundamental economics and outcomes of discovery processes. The platform's self-learning system integrates seamlessly into scientific workflows and becomes more intelligent with every experiment conducted.
